Ibrutinib in the Real World Patient: Many Lights and Some Shades

Overview

Journal Haematologica

Specialty Hematology

Date 2016 Dec 2

PMID 27903711

Citations 11

Authors

Paolo Ghia

Antonio Cuneo

Affiliations

Soon will be listed here.

Citing Articles

Real world outcomes with Ibrutinib monotherapy in chronic lymphocytic leukemia: a single center experience.

Mesaros O, Jimbu L, Rus I, Parvu A, Tomuleasa C, Dima D Med Pharm Rep. 2025; 98(1):36-45.

PMID: 39949913 PMC: 11817578. DOI: 10.15386/mpr-2800.

First-Line Treatment of Older Patients with CLL: A New Approach in the Chemo-Free Era.

Urso A, Cavazzini F, Ballardini M, Gambara S, Consolo S, Rigolin G Cancers (Basel). 2023; 15(15).

PMID: 37568676 PMC: 10417156. DOI: 10.3390/cancers15153859.

Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency.

Rigolin G, Olimpieri P, Summa V, Celant S, Scarfo L, Tognolo L Blood Cancer J. 2023; 13(1):99.

PMID: 37380630 PMC: 10307816. DOI: 10.1038/s41408-023-00865-z.

Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study.

Mauro F, Paoloni F, Molica S, Reda G, Trentin L, Sportoletti P Cancers (Basel). 2022; 14(1).

PMID: 35008372 PMC: 8750939. DOI: 10.3390/cancers14010207.

Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group.

Rigolin G, Cavazzini F, Piciocchi A, Arena V, Visentin A, Reda G Hematol Oncol. 2021; 39(3):326-335.

PMID: 33739461 PMC: 8451799. DOI: 10.1002/hon.2861.

References

Yancik R . Cancer burden in the aged: an epidemiologic and demographic overview. Cancer. 1997; 80(7):1273-83. View

Hallek M . Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment. Am J Hematol. 2015; 90(5):446-60. DOI: 10.1002/ajh.23979. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2015. CA Cancer J Clin. 2015; 65(1):5-29. DOI: 10.3322/caac.21254. View

Byrd J, Furman R, Coutre S, Flinn I, Burger J, Blum K . Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013; 369(1):32-42. PMC: 3772525. DOI: 10.1056/NEJMoa1215637. View

Byrd J, Brown J, OBrien S, Barrientos J, Kay N, Reddy N . Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014; 371(3):213-23. PMC: 4134521. DOI: 10.1056/NEJMoa1400376. View

Farooqui M, Valdez J, Martyr S, Aue G, Saba N, Niemann C . Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol. 2015; 16(2):169-76. PMC: 4342187. DOI: 10.1016/S1470-2045(14)71182-9. View

Rossi D, Terzi-di-Bergamo L, De Paoli L, Cerri M, Ghilardi G, Chiarenza A . Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. Blood. 2015; 126(16):1921-4. PMC: 4743433. DOI: 10.1182/blood-2015-05-647925. View

Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O . Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010; 116(19):3724-34. DOI: 10.1182/blood-2010-05-282632. View

. Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients. Haematologica. 2016; 101(12):1563-1572. PMC: 5479600. DOI: 10.3324/haematol.2016.147900. View

10.

Winqvist M, Asklid A, Andersson P, Karlsson K, Karlsson C, Lauri B . Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group. Haematologica. 2016; 101(12):1573-1580. PMC: 5479603. DOI: 10.3324/haematol.2016.144576. View

11.

Fischer K, Bahlo J, Fink A, Goede V, Herling C, Cramer P . Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2015; 127(2):208-15. DOI: 10.1182/blood-2015-06-651125. View

12.

Foa R, Guarini A . A mechanism-driven treatment for chronic lymphocytic leukemia?. N Engl J Med. 2013; 369(1):85-7. DOI: 10.1056/NEJMe1303054. View

13.

Thompson P, Tam C, OBrien S, Wierda W, Stingo F, Plunkett W . Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 2015; 127(3):303-9. PMC: 4760129. DOI: 10.1182/blood-2015-09-667675. View

14.

Mato A, Nabhan C, Barr P, Ujjani C, Hill B, Lamanna N . Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience. Blood. 2016; 128(18):2199-2205. DOI: 10.1182/blood-2016-05-716977. View

15.

Herishanu Y, Goldschmidt N, Bairey O, Ruchlemer R, Fineman R, Rahimi-Levene N . Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience. Haematologica. 2015; 100(5):662-9. PMC: 4420215. DOI: 10.3324/haematol.2014.115808. View

16.

Jain P, Keating M, Wierda W, Estrov Z, Ferrajoli A, Jain N . Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood. 2015; 125(13):2062-7. PMC: 4467871. DOI: 10.1182/blood-2014-09-603670. View

17.

OBrien S, Jones J, Coutre S, Mato A, Hillmen P, Tam C . Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016; 17(10):1409-1418. DOI: 10.1016/S1470-2045(16)30212-1. View

18.

Ghia P . Ibrutinib holds promise for patients with 17p deletion CLL. Lancet Oncol. 2016; 17(10):1342-1343. DOI: 10.1016/S1470-2045(16)30442-9. View

19.

Byrd J, Furman R, Coutre S, Burger J, Blum K, Coleman M . Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015; 125(16):2497-506. PMC: 4400288. DOI: 10.1182/blood-2014-10-606038. View